AGEN

$3.99

Market ClosedAs of Mar 17, 8:00 PM UTC

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.99
Potential Upside
5%
Whystock Fair Value$4.19
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression pla...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$144.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.03

Recent News

Zacks
Mar 17, 2026

Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Mar 16, 2026

Agenus: Q4 Earnings Snapshot

LEXINGTON, Mass. AP) — Agenus Inc. AGEN) on Monday reported a loss of $10.6 million in its fourth quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 13, 2026

CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Feb 24, 2026

Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC

Agenus Inc. (NASDAQ:AGEN) is one of the most undervalued penny stocks to buy right now. On February 19, Agenus presented new translational and clinical biomarker data from its Phase 1b C-800-01 trial, focusing on the combination of botensilimab/BOT and balstilimab/BAL. The study highlighted the therapy’s effectiveness in immunologically cold tumors, such as microsatellite-stable metastatic colorectal […]

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Jan 29, 2026

Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch

Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a recently closed manufacturing collaboration with Zydus Lifesciences, the expansion of France’s reimbursed e

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.